Characteristics of Adverse Events Following Immunization Reporting in Children: The Japanese Adverse Drug Event Report Database.
adverse events following immunization
children
spontaneous reports
vaccine
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
03 Jul 2020
03 Jul 2020
Historique:
received:
29
05
2020
revised:
30
06
2020
accepted:
30
06
2020
entrez:
9
7
2020
pubmed:
9
7
2020
medline:
9
7
2020
Statut:
epublish
Résumé
The present study aimed to describe the trends and characteristics of adverse events following immunization (AEFI) reporting for children in the Japanese Adverse Drug Event Report database (JADER). We used 6280 AEFI reports for children aged <19 years among 504,407 ADR reports included in the JADER from 2004 to 2017. The number of AEFI reports gradually increased among children aged <10 years and was the highest in 2011 among children aged 10-19 years. The number of suspected vaccines per AEFI report increased after 2011 among children aged <10 years. The percentage of "death" and "did not recover" as AEFI outcomes reported were 4.3% and 3.7% among children aged <10 years and 0.2% and 21.1% among children aged 10-19 years, respectively. The most frequently reported vaccine-reaction pair was
Identifiants
pubmed: 32635349
pii: vaccines8030357
doi: 10.3390/vaccines8030357
pmc: PMC7564739
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : the Ministry of Health, Labour and Welfare of Japan
ID : H24-iyakuwakate-011
Organisme : the Japan Agency for Medical Research and Development
ID : 17mk0101095h0001
Organisme : the Japan Agency for Medical Research and Development
ID : 18mk0101095h0002
Références
Lancet. 1994 Aug 6;344(8919):408-9
pubmed: 7914330
PLoS One. 2015 Jun 19;10(6):e0130399
pubmed: 26090678
Pharmacoepidemiol Drug Saf. 2005 Jul;14(7):493-9
pubmed: 15918163
EBioMedicine. 2016 Oct;12:295-301
pubmed: 27658738
Papillomavirus Res. 2018 Jun;5:96-103
pubmed: 29481964
Drug Saf. 2014 Apr;37(4):283-94
pubmed: 24643967
Expert Opin Drug Saf. 2016 Oct;15(10):1321-8
pubmed: 27501085
Eur J Clin Pharmacol. 2012 Sep;68(9):1329-38
pubmed: 22415248
Pharmacoepidemiol Drug Saf. 2020 Feb;29(2):173-181
pubmed: 31823506
PLoS One. 2016 Jun 01;11(6):e0155385
pubmed: 27249414
Int J Clin Pharm. 2020 Apr;42(2):728-736
pubmed: 32020439
Br J Clin Pharmacol. 2016 Dec;82(6):1601-1612
pubmed: 27597136
MMWR Surveill Summ. 2003 Jan 24;52(1):1-24
pubmed: 12825543
Drug Saf. 2012 Dec 1;35(12):1171-82
pubmed: 23072620
Lancet Public Health. 2020 Apr;5(4):e184-e185
pubmed: 32243849
Drug Saf. 2017 Nov;40(11):1141-1146
pubmed: 28664356